Purchase this article with an account.
I. Tsui, T. A. McCannel, S. C. N. Oliver, M. W. Chun, L. H. Kobe, M. Y. Leu, S. P. Lee, F. Yu, T. Nulliah, B. R. Straatsma; Central Vision After Treatment of Ciliochoroidal Melanoma With Iodine-125 Brachytherapy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5705.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report best-corrected visual acuity, contrast sensitivity and color vision in patients with ciliochoroidal melanoma prior to, six months after and one year after treatment with Iodine-125 brachytherapy.
Prospective single center cohort study of best-corrected visual acuity, contrast sensitivity and color vision in 40 patients (40 eyes) with medium-sized ciliochoroidal melanoma treated with Iodine-125 brachytherapy at a dose of 8,500 rads to the tumor apex. Best-corrected visual acuity assessed after COMS protocol refraction using the ETDRS chart, Pelli-Robinson contrast sensitivity and HRR color vision were assessed within one month prior to, six months after and one year after brachytherapy. Melanoma dimensions were assessed by ultrasonography at the same intervals.
40 patients (40 eyes) had a mean age of 58 years (range 30-78 years). Prior to, six months after and one year after brachytherapy, mean best-corrected visual acuity was 47 (20/30), 40 (20/50), 38 (20/63) ETDRS letters respectively; mean Pelli-Robinson contrast sensitivity was 30 (4.4%), 26 (6.2%), 26 (6.2%) letters; mean HRR color vision was 13/14, 10,/14 10/14. Visual acuity and contrast sensitivity at six months and one year were inversely correlated to baseline tumor height.
This prospective study evaluated best-corrected ETDRS visual acuity, contrast sensitivity, and color vision after brachytherapy for ciliochoroidal melanoma. Following brachytherapy, eyes treated showed a statistically significant change in visual function; central visual function at six months and one year was inversely related to baseline tumor height.
This PDF is available to Subscribers Only